CAS: 41451-91-6; Erythromycin E
该化合物是来自血细胞沙迦罗oplyspora 红血病的大型抗生素,它展示了广泛的抗菌活动,特别是针对抗乳性细菌和某些抗乳性生物的抗菌活动.乙烯色素E的结构具有大型的内酯酶环,该环是大型的大型内酯环的特征,它含有多种有助于其生物活动的氢氧基和氯酮功能组.该化合物通过将细菌蛋白合成与50-S的肋骨质亚元素结合,有效阻断了转化步骤.乙酰胺E经常用于临床环境中治疗各种感染,包括呼吸道感染,皮肤感染和某些性传染疾病.其药理学包括口服吸收,主要发生在肝脏中,它通常具有新陈代谢作用.它能够造成胃肠胃侧效应,并可能与其他药物相互作用,因为其对肝脏感染的治疗具有重要影响.
- 英文名称Erythromycin E
- 中文名称红霉素杂质 C
- 其它别名Spiro[5H,11H-1,3-dioxino[5,4-c]oxacyclotetradecin-2,2'-[2H]pyran],erythromycin deriv.; Erythromycin E
- CAS编号41451-91-6
- FDA UNII编号:39V2DI8XOX
- 分子式:C37H65NO14分子量:747.91
- 产品CID: 1428834
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-02064608-A1
优先权日:2000-11-29
标 题:Synthesis and separation of optically active isomers of erythromycin and their biological actions
发明人：SOMBERG JOHN C; RANADE VASANT
权利人:ACADEMIC PHARM INC; SOMBERG JOHN C; RANADE VASANT
摘要:The present invention provides methods for purifying and using optically active isomers of erythromycin as well as compositions comprising such optically active isomers. Such optically active isomers having desired actions as an antibiotic substantially separable from undesirable effects on GI motility and the cardiac potassium channels such that the cardiac action potential is not prolonged and the QT interval on the surface EKG (electrocardiogram) is not increased, such that the erythromycin can be useful for more effective therapy of systemic infections. Also disclosed are methods for assaying the levels of such isomers present in the biological fluids.
专利号:EP-1339731-A1
优先权日:2000-11-29
标题:Synthesis and separation of optically active isomers of erythromycin and their biological actions
专利号:CA-2430233-A1
优先权日:2000-11-29
标题 :Synthesis and separation of optically active isomers of erythromycin and their biological actions
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
参考文献:10.1046/j.1469-0691.2002.00347.x
摘要:King A, Bathgate T, Phillips I. Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin. Clin Microbiol Infect. 2002 Feb;8(2):85–92. doi: 10.1046/j.1469-0691.2002.00347.x.
📝 需求与反馈
尽可能描述清楚需求与问题信息
